HK1023499A1 - Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a - Google Patents

Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a

Info

Publication number
HK1023499A1
HK1023499A1 HK00100407A HK00100407A HK1023499A1 HK 1023499 A1 HK1023499 A1 HK 1023499A1 HK 00100407 A HK00100407 A HK 00100407A HK 00100407 A HK00100407 A HK 00100407A HK 1023499 A1 HK1023499 A1 HK 1023499A1
Authority
HK
Hong Kong
Prior art keywords
compositions containing
vaccine compositions
monophosphoryl lipid
deacylated monophosphoryl
deacylated
Prior art date
Application number
HK00100407A
Other languages
English (en)
Inventor
Pierre Hauser
Pierre Voet
Moncef Slaoui
Nathalie Garcon-Johnson
Marie-Josephe Claude
Pierre Desmons
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26302633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1023499(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB939306029A external-priority patent/GB9306029D0/en
Priority claimed from GB9403417A external-priority patent/GB9403417D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of HK1023499A1 publication Critical patent/HK1023499A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HK00100407A 1993-03-23 1998-12-10 Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a HK1023499A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939306029A GB9306029D0 (en) 1993-03-23 1993-03-23 Vaccine compositions
GB9403417A GB9403417D0 (en) 1994-02-23 1994-02-23 Vaccine compositions

Publications (1)

Publication Number Publication Date
HK1023499A1 true HK1023499A1 (en) 2000-09-15

Family

ID=26302633

Family Applications (3)

Application Number Title Priority Date Filing Date
HK00100407A HK1023499A1 (en) 1993-03-23 1998-12-10 Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
HK98113156A HK1011930A1 (en) 1993-03-23 1998-12-10 Vaccine compositions containing 3-o deacylated monoposphoryl lipid a
HK02105614.3A HK1045935A1 (zh) 1993-03-23 2002-07-30 含有3-o脫酰基單磷酰酯a的疫苗組合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK98113156A HK1011930A1 (en) 1993-03-23 1998-12-10 Vaccine compositions containing 3-o deacylated monoposphoryl lipid a
HK02105614.3A HK1045935A1 (zh) 1993-03-23 2002-07-30 含有3-o脫酰基單磷酰酯a的疫苗組合物

Country Status (28)

Country Link
US (1) US5776468A (da)
EP (3) EP1175912A1 (da)
JP (2) JP4028593B2 (da)
KR (1) KR100310510B1 (da)
CN (1) CN1087176C (da)
AP (1) AP515A (da)
AT (2) ATE157882T1 (da)
AU (1) AU685443B2 (da)
BR (1) BR9405957A (da)
CZ (1) CZ289476B6 (da)
DE (2) DE69428136T3 (da)
DK (2) DK0689454T4 (da)
DZ (1) DZ1763A1 (da)
ES (2) ES2162139T5 (da)
FI (1) FI110844B (da)
GR (1) GR3025483T3 (da)
HK (3) HK1023499A1 (da)
HU (1) HU219056B (da)
IL (1) IL109056A (da)
MA (1) MA23143A1 (da)
NO (2) NO322578B1 (da)
NZ (1) NZ263538A (da)
PL (1) PL178578B1 (da)
PT (1) PT812593E (da)
SA (1) SA94140762B1 (da)
SG (1) SG48309A1 (da)
SK (1) SK117395A3 (da)
WO (1) WO1994021292A1 (da)

Families Citing this family (423)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
PT835663E (pt) * 1992-05-23 2010-01-04 Glaxosmithkline Biolog Sa Vacinas combinadas compreendendo o antigénio de superfície da hepatite b e outros antigénios
AU676340B2 (en) * 1993-05-25 1997-03-06 Wyeth Holdings Corporation Adjuvants for vaccines against respiratory syncytial virus
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6696065B1 (en) * 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
AU1463097A (en) 1996-01-04 1997-08-01 Rican Limited Helicobacter pylori bacterioferritin
US7517952B1 (en) * 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20060269532A1 (en) * 1997-02-25 2006-11-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
NZ338101A (en) * 1997-04-01 2002-03-28 Corixa Corp Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
EP1089756A4 (en) * 1998-05-22 2002-07-17 Smithkline Beecham Corp CORRELATIVE PROTECTION USING OspA ANTIBODY TITLES
JP2002520373A (ja) * 1998-07-14 2002-07-09 アメリカン・サイアナミド・カンパニー モノホスホリルリピドａを含有するアジュバントおよびワクチン組成物
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
US20040213806A1 (en) * 1998-08-28 2004-10-28 Smithkline Beecham Biologicals, S.A. Salmonella typhi vaccine compositions
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
DE69935606T9 (de) * 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
AU1580300A (en) 1998-12-08 2000-06-26 Smithkline Beecham Biologicals (Sa) Novel compounds
DK1163343T3 (da) 1999-03-12 2010-04-19 Glaxosmithkline Biolog Sa Neisseria meningitidis antigene polypeptider, tilsvarende polynukleotider og beskyttende antistoffer
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
MY125387A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
EP2322210A1 (en) 1999-04-19 2011-05-18 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
GEP20053446B (en) * 1999-05-13 2005-02-25 Wyeth Corp Adjuvant Combination Formulations
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1104767A1 (en) 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
DK1282702T3 (da) 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CA2436107C (en) * 2000-10-06 2012-05-22 H. Henrich Paradies Kyberdrug as autovaccines with immune-regulating effects
DK1889630T3 (da) 2000-10-18 2012-03-05 Glaxosmithkline Biolog Sa Vacciner omfattende MAGE-antigen koblet til protein D-fragment
NZ560966A (en) 2000-10-27 2010-06-25 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
US7048931B1 (en) * 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1343527A2 (en) * 2000-11-10 2003-09-17 American Cyanamid Company Adjuvant combination formulations
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
JP2004535765A (ja) 2000-12-07 2004-12-02 カイロン コーポレイション 前立腺癌においてアップレギュレートされた内因性レトロウイルス
EP2269639B1 (en) 2001-02-23 2018-11-28 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
SI1549338T1 (sl) 2002-10-11 2011-04-29 Novartis Vaccines & Diagnostic Polipeptidna cepiva za ĺ iroko zaĺ äśito pred hipervirulentnimi miningokoknimi rodovi
US8232255B2 (en) 2002-10-23 2012-07-31 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
ES2411080T3 (es) 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
PL1961426T3 (pl) 2003-10-02 2012-03-30 Gsk Vaccines S R L Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
DE602004028262D1 (de) 2003-10-02 2010-09-02 Glaxosmithkline Biolog Sa B. pertussis antigene und ihre verwendung bei der vakzinierung
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
SI1740217T1 (sl) 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP2848692B1 (en) 2004-05-21 2017-08-16 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
CA2565500A1 (en) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US20080095777A1 (en) 2004-09-22 2008-04-24 Glaxosmithkline Biologicals S.A. Immunogenic Composition for Use in Vaccination Against Staphylococcei
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2006062637A2 (en) 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics Inc. Influenza vaccination
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
EP1838854B1 (en) * 2004-12-15 2012-10-31 Janssen Alzheimer Immunotherapy Antibodies that recognize Beta Amyloid Peptide
NZ555937A (en) 2005-01-27 2009-05-31 Childrens Hosp & Res Ct Oak GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
NZ560930A (en) * 2005-02-16 2011-06-30 Novartis Vaccines & Diagnostic Hepatitis B virus vaccine comprising a hepatitis B virus surface antigen, aluminium phosphate, 3-O-deacylated monophosphoryl lipid A and a triethylammonium ion
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
EP1858919B1 (en) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
LT2351772T (lt) 2005-02-18 2016-10-10 Glaxosmithkline Biologicals Sa Baltymai ir nukleorūgštys iš su meningitu/sepsiu susijusių escherichia coli
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
US20090081253A1 (en) 2005-03-23 2009-03-26 Glaxosmithkline Biologicals S.A. Composition
CA2605179A1 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics, Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
PL2426141T3 (pl) 2005-04-29 2015-02-27 Glaxosmithkline Biologicals Sa Sposób profilaktyki lub leczenia zakażenia m. tuberculosis
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP2357000A1 (en) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US10842867B2 (en) 2005-11-04 2020-11-24 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
BRPI0618254A2 (pt) * 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
AU2006310337B9 (en) 2005-11-04 2013-11-28 Novartis Ag Adjuvanted influenza vaccines including cytokine-inducing agents
ATE539765T1 (de) 2005-11-04 2012-01-15 Novartis Vaccines & Diagnostic Grippeimpfstoffe mit kombinationen aus teilchenförmigen adjuvantien und immunverstärkern
NZ567978A (en) 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
NO346529B1 (no) 2005-12-22 2022-09-26 Glaxosmithkline Biologicals Sa Bruk av et immunogenpreparat for småbarn, omfattende 22F sakkaridkonjugat
MY150105A (en) 2006-01-17 2013-11-29 Forsgren Arne A novel surface exposed haemophilus influenzae protein (protein e; pe)
EP1976559B3 (en) 2006-01-27 2020-02-19 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
JP2009531387A (ja) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2035035A2 (en) 2006-06-09 2009-03-18 Novartis AG Immunogenic compositions for streptococcus agalactiae
PL2422810T3 (pl) 2006-07-17 2015-03-31 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
EP2040742B1 (en) 2006-07-18 2014-10-29 GlaxoSmithKline Biologicals S.A. Vaccines for malaria
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CN101516396B (zh) 2006-09-26 2013-10-09 传染性疾病研究院 包含合成佐剂的疫苗组合物
HUE032422T2 (en) 2006-09-29 2017-09-28 Takeda Vaccines Inc Norovirus vaccine preparations
MX2009003325A (es) 2006-10-12 2009-04-09 Glaxosmithkline Biolog Sa Vacuna que comprende un adyuvante de emulsion de aceite en agua.
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
EA200900784A1 (ru) 2006-12-06 2009-12-30 Новартис Аг Вакцины, включающие антиген из четырех штаммов вируса гриппа
CL2008000611A1 (es) 2007-03-02 2008-09-05 Glaxosmithkline Biolog Sa Procedimiento para fomentar respuesta inmunitaria frente a un patogeno que comprende administrar i) uno o mas polipeptidos inmunogenicos derivados del patogeno, ii) uno o mas vectores adenoviricos que comprenden uno o mas polinucleotidos que codifica
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
CN101883583B (zh) 2007-06-26 2017-05-17 葛兰素史密丝克莱恩生物有限公司 含有肺炎链球菌荚膜多糖缀合物的疫苗
EP2185191B1 (en) 2007-06-27 2012-09-12 Novartis AG Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
DK2173376T3 (da) * 2007-08-02 2015-06-29 Biondvax Pharmaceuticals Ltd Multimere multiepitop-influenzavacciner
CA2695421A1 (en) 2007-08-03 2009-02-12 President And Fellows Of Harvard College Chlamydia antigens
CA2695477A1 (en) 2007-08-13 2009-02-19 Glaxosmithkline Biologicals S.A. Infant plasmodium falciparum cs vaccines
MX2010002773A (es) 2007-09-12 2010-03-31 Novartis Ag Antigenos mutantes de gas57 y anticuerpos de gas57.
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CA2744739A1 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
WO2009117035A1 (en) 2007-12-19 2009-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2537857B1 (en) 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutant forms of streptolysin O
DK2222710T3 (da) * 2007-12-24 2016-10-03 Id Biomedical Corp Quebec Rekombinante RSV-antigener.
CN102356089B (zh) 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
WO2009114485A2 (en) 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
EP2889042A3 (en) 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
WO2009127676A1 (en) 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
AU2009248810B2 (en) 2008-05-23 2013-12-05 The Regents Of The University Of Michigan Nanoemulsion vaccines
EA201170217A1 (ru) * 2008-07-18 2011-08-30 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК Гибридные полипептидные антигены респираторно-синцитиального вируса
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
CA2738245A1 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2376089B1 (en) 2008-11-17 2018-03-14 The Regents of the University of Michigan Cancer vaccine compositions and methods of using the same
BRPI0922132A2 (pt) 2008-12-03 2018-10-23 Protea Vaccine Tech Ltd fragmentos glutamil trna sintetase (gts).
PE20142330A1 (es) 2008-12-09 2015-01-14 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
CN103897045A (zh) 2009-01-12 2014-07-02 诺华股份有限公司 抗革兰氏阳性细菌疫苗中的Cna_B结构域
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
CA2750055A1 (en) 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Method for purifying viruses using a density gradient
ES2608841T3 (es) 2009-02-10 2017-04-17 Seqirus UK Limited Vacunas contra la gripe con cantidades reducidas de escualeno
BRPI1011224A2 (pt) 2009-02-17 2016-03-15 Glaxosmithkline Biolog Sa vacina contra vírus da dengue inativado com adjuvante livre de alumínio
AU2010220824A1 (en) 2009-03-05 2011-10-20 Jenny Colleen Mccloskey Treatment of infection
ES2733084T3 (es) 2009-03-06 2019-11-27 Glaxosmithkline Biologicals Sa Antígenos de Chlamydia
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
BRPI1013780B8 (pt) 2009-04-14 2022-10-04 Novartis Ag Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
CA2757620C (en) 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
EP2944320A1 (en) 2009-06-15 2015-11-18 National University of Singapore Influenza vaccine, composition, and methods of use
EP2442827B1 (en) 2009-06-16 2016-01-06 The Regents of the University of Michigan Nanoemulsion vaccines
PE20121541A1 (es) 2009-06-24 2012-12-21 Glaxosmithkline Biolog Sa Antigenos de virus de sincicio respiratorio recombinantes
WO2010149743A2 (en) 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine
CA2767536A1 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
EP4218799A1 (en) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
CA2768343A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
WO2011013034A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CN104548089B (zh) 2009-09-03 2017-09-26 辉瑞疫苗有限责任公司 Pcsk9疫苗
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
US9341623B2 (en) 2009-09-25 2016-05-17 Glaxosmithkline Biologicals Sa Immunodiffusion assay for influenza virus
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
EP2483390A2 (en) 2009-09-30 2012-08-08 Novartis AG Expression of meningococcal fhbp polypeptides
JP2013506651A (ja) 2009-09-30 2013-02-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ．ａｕｒｅｕｓ５型および８型莢膜多糖の結合体
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
DE102009056871A1 (de) * 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
JP6007105B2 (ja) 2009-12-22 2016-10-12 セルデックス・セラピューティクス・インコーポレイテッド ワクチン組成物
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
EA201290956A1 (ru) 2010-03-26 2013-04-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина против вич
CA2790167C (en) 2010-03-30 2021-02-09 Children's Hospital & Research Center Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2556151A1 (en) 2010-04-07 2013-02-13 Novartis AG Method for generating a parvovirus b19 virus-like particle
US9597326B2 (en) 2010-04-13 2017-03-21 Glaxosmithkline Biologicals Sa Benzonapthyridine compositions and uses thereof
BR112012027643A2 (pt) 2010-05-03 2016-08-16 Glaxosmithkline Biolog Sa métodos para a inativação de um orthomixovírus, para a preparação de uma vacina, e , composição imunogênica
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
EP3153578A1 (en) 2010-07-06 2017-04-12 Novartis Ag Norovirus derived immunogenic compositions and methods
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CA2812893A1 (en) 2010-09-27 2012-04-05 Glaxosmithkline Biologicals S.A. Vaccine
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
TW201305190A (zh) 2010-10-15 2013-02-01 Glaxosmithkline Biolog Sa 新穎之抗原
FR2966044B1 (fr) * 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012072088A1 (en) 2010-12-02 2012-06-07 Bionor Immuno As Peptide scaffold design
SG190731A1 (en) 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
CA2821995C (en) 2011-01-06 2019-02-12 Bionor Immuno As Monomeric and multimeric peptides immunogenic against hiv
US10342862B2 (en) 2011-01-26 2019-07-09 Glaxosmithkline Biologicals, Sa RSV immunization regimen
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
EP2680883B1 (en) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9 vaccine
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
LT3275892T (lt) 2011-05-13 2020-04-10 Glaxosmithkline Biologicals S.A. Struktūros prieš suliejimą rsv f antigenai
EA201391456A1 (ru) 2011-05-17 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. ВАКЦИНА ПРОТИВ Streptococcus pneumoniae
JP6109165B2 (ja) * 2011-07-01 2017-04-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヘルペスウイルスワクチンおよび使用方法
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
JP2014520807A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー 免疫原性組成物およびその使用
JP6088507B2 (ja) 2011-07-08 2017-03-01 ノバルティス アーゲー チロシンライゲーションの方法
CN105031637A (zh) 2011-07-11 2015-11-11 武田疫苗股份有限公司 胃肠外诺如病毒疫苗配制剂
WO2013016460A1 (en) 2011-07-25 2013-01-31 Novartis Ag Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
JP2014525429A (ja) 2011-09-01 2014-09-29 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
MX2014002769A (es) 2011-09-16 2014-06-11 Ucb Pharma Sa Anticuerpos neutralizantes para las exotoxinas principales tcda y tcdb de clostridium difficile.
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
US20150030630A1 (en) 2012-03-07 2015-01-29 Novartis Ag Adjuvanted formulations of rabies virus immunogens
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
CN104203270A (zh) 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
EP2833900B1 (en) 2012-04-01 2018-09-19 Technion Research & Development Foundation Limited Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
CN107746852B (zh) 2012-05-04 2021-10-08 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
JP2015518845A (ja) 2012-05-22 2015-07-06 ノバルティス アーゲー 髄膜炎菌血清群ｘコンジュゲート
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
CA2874923C (en) 2012-06-06 2021-08-31 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
EP2869842A1 (en) 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
WO2014024026A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
EP2892553A1 (en) 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
CN105307684A (zh) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 非直链糖缀合物
ES2848048T3 (es) 2012-10-03 2021-08-05 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas
SG11201502599TA (en) 2012-10-12 2015-05-28 Glaxosmithkline Biolog Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
RU2018137673A (ru) 2012-11-30 2019-03-22 Глаксосмитклайн Байолоджикалс Са Антигены и комбинации антигенов pseudomonas
PT3513806T (pt) 2012-12-05 2023-03-02 Glaxosmithkline Biologicals Sa Composição imunogénica
ES2924914T3 (es) 2013-03-15 2022-10-11 Glaxosmithkline Biologicals Sa Vacuna contra rinovirus humano
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
JP2016520077A (ja) 2013-05-15 2016-07-11 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ Ｅ１ｅ２ｈｃｖワクチン及び使用方法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
AU2014304545A1 (en) 2013-08-05 2016-02-25 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
WO2015028546A1 (en) 2013-08-30 2015-03-05 Glaxosmithkline Biologicals S.A. Large scale production of viruses in cell culture
EP3063171B1 (en) 2013-11-01 2019-07-24 University Of Oslo Albumin variants and uses thereof
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
NZ759686A (en) 2014-01-21 2023-07-28 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
EP3122379A1 (en) * 2014-03-25 2017-02-01 The Government of the United States of America as represented by the Secretary of the Army Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
ES2769647T3 (es) 2014-03-26 2020-06-26 Glaxosmithkline Biologicals Sa Antígenos estafilocócicos mutantes
EP3154576A1 (en) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
EP3636278A3 (en) 2014-06-25 2020-07-15 GlaxoSmithKline Biologicals S.A. Clostridium difficile immunogenic composition
CN106715458A (zh) 2014-07-18 2017-05-24 华盛顿大学 癌症疫苗组合物及其使用方法
WO2016012385A1 (en) 2014-07-21 2016-01-28 Sanofi Pasteur Vaccine composition comprising ipv and cyclodextrins
BR112017001417B1 (pt) 2014-07-23 2023-11-07 Children's Hospital & Research Center At Oakland Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada
ES2924988T3 (es) 2014-10-10 2022-10-13 Univ Michigan Regents Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
MA40920A (fr) 2014-11-07 2017-09-12 Takeda Vaccines Inc Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
HUE062499T2 (hu) 2015-01-15 2023-11-28 Pfizer Pneumococcus-vakcinákban történõ alkalmazásra szolgáló immunogén készítmények
EP4226936A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
WO2016154010A1 (en) 2015-03-20 2016-09-29 Makidon Paul Immunogenic compositions for use in vaccination against bordetella
CA2986494A1 (en) 2015-06-03 2016-12-08 Affiris Ag Il-23-p19 vaccines
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
US20180186896A1 (en) 2015-07-07 2018-07-05 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
RU2721128C2 (ru) 2015-07-21 2020-05-18 Пфайзер Инк. Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
BR112018067897A2 (pt) 2016-03-14 2019-04-24 Univ Oslo imunoglobulinas modificadas com ligação de fcrn alterada
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
EP3471761A2 (en) 2016-06-21 2019-04-24 University Of Oslo Hla binding vaccine moieties and uses thereof
CA3034124A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
CN110035770B (zh) 2016-12-07 2023-06-16 葛兰素史密丝克莱恩生物有限公司 新方法
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
WO2018109220A2 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
RU2762723C2 (ru) 2017-01-20 2021-12-22 Пфайзер Инк. Иммуногенные композиции для применения в пневмококковых вакцинах
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
JP2020515587A (ja) 2017-03-31 2020-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 免疫原性組成物、使用及び処置方法
KR102595238B1 (ko) 2017-04-19 2023-10-26 인스티튜트 포 리서치 인 바이오메드슨 말라리아원충 종충에 결합하는 신규한 말라리아 백신 및 항체.
EP3615061A1 (en) 2017-04-28 2020-03-04 GlaxoSmithKline Biologicals S.A. Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
WO2019034575A1 (en) 2017-08-14 2019-02-21 Glaxosmithkline Biologicals Sa METHODS OF AMPLIFYING IMMUNE RESPONSES
EP3678698A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
US20200276299A1 (en) 2017-09-08 2020-09-03 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
EP3703741A1 (en) 2017-11-03 2020-09-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
US11702674B2 (en) 2018-06-12 2023-07-18 Glaxosmithkline Biologicals Sa Simian adenovirus vectors comprising the ChAd-157 fiber protein
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
CN110680909A (zh) * 2018-07-04 2020-01-14 辽宁成大生物股份有限公司 一种速释b型流感嗜血杆菌结合疫苗可溶性微针贴及其制备方法
US20210292395A1 (en) 2018-07-31 2021-09-23 Glaxosmithkline Biologicals Sa Antigen purification method
CA3107077A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
CN112912097A (zh) 2018-08-23 2021-06-04 葛兰素史密丝克莱恩生物有限公司 免疫原性蛋白和组合物
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020115171A1 (en) 2018-12-06 2020-06-11 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US20220184158A1 (en) 2018-12-21 2022-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220339281A1 (en) 2019-03-05 2022-10-27 GalxoSmithKline Biologicals SA Hepatitis b immunisation regimen and compositions
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3956666A1 (en) 2019-04-18 2022-02-23 GlaxoSmithKline Biologicals S.A. Antigen binding proteins and assays
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CA3148928A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
AU2020325645A1 (en) 2019-08-05 2022-02-17 Glaxosmithkline Biologicals Sa Immunogenic composition
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
MX2022002823A (es) 2019-09-09 2022-10-21 Glaxosmithkline Biologicals Sa Composiciones inmunoterapeuticas.
CN114667343A (zh) 2019-11-01 2022-06-24 辉瑞大药厂 大肠杆菌组合物及其方法
US20230045642A1 (en) 2019-12-19 2023-02-09 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
NL2027383B1 (en) 2020-01-24 2022-04-06 Aim Immunotech Inc Methods, compositions, and vaccines for treating a virus infection
EP4103587A1 (en) 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine
US20230085173A1 (en) 2020-02-21 2023-03-16 Pfizer Inc. Purification of saccharides
BR112022014555A2 (pt) 2020-02-23 2022-09-20 Pfizer Composições de escherichia coli e métodos das mesmas.
US20230277657A1 (en) 2020-05-05 2023-09-07 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
WO2022029024A1 (en) 2020-08-03 2022-02-10 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
AU2021368151A1 (en) 2020-10-27 2023-06-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CN116744965A (zh) 2020-11-04 2023-09-12 辉瑞大药厂 用于肺炎球菌疫苗的免疫原性组合物
EP4243863A2 (en) 2020-11-10 2023-09-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4255919A2 (en) 2020-12-02 2023-10-11 GlaxoSmithKline Biologicals S.A. Donor strand complemented fimh
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CA3210363A1 (en) 2021-02-11 2022-08-18 Glaxosmithkline Biologicals Sa Hpv vaccine manufacture
WO2022178196A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
CA3215344A1 (en) 2021-04-30 2022-11-03 Kalivir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
BR112023023671A2 (pt) 2021-05-28 2024-02-06 Pfizer Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
CA3237496A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
GB202215634D0 (en) 2022-10-21 2022-12-07 Glaxosmithkline Biologicals Sa Polypeptide scaffold

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US703355A (en) * 1901-11-05 1902-06-24 Bertt H Brockway Current-motor.
US4196192A (en) * 1977-10-28 1980-04-01 American Cyanamid Company Combined Haemophilus influenzae type b and pertussis vaccine
US4620978A (en) * 1982-04-07 1986-11-04 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis A virus purified and triply cloned
GB8508685D0 (en) * 1985-04-03 1985-05-09 Minor P D Peptides
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE3916595A1 (de) * 1989-05-22 1990-11-29 Boehringer Mannheim Gmbh Verfahren zur nichtradioaktiven messung der nucleinsaeuresynthese in eukaryontischen zellen
DE69031556T2 (de) * 1989-07-25 1998-05-14 Smithkline Beecham Biolog Antigene sowie Verfahren zu deren Herstellung
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
CH678394A5 (da) * 1990-08-22 1991-09-13 Cerny Erich H
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
JPH06501151A (ja) * 1990-09-28 1994-02-10 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ｇｐ１６０の誘導体およびアジュバントを含有するｇｐ１６０またはその誘導体に基づくワクチン
AU9052091A (en) * 1990-12-20 1992-07-22 Smithkline Beecham Biologicals (Sa) Vaccines based on hepatitis b surface antigen
GB9028038D0 (en) * 1990-12-24 1991-02-13 Nycomed Pharma As Test method and reagent kit therefor
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
AU6141094A (en) * 1993-02-19 1994-09-14 Smithkline Beecham Biologicals (Sa) Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a

Also Published As

Publication number Publication date
CZ289476B6 (cs) 2002-01-16
PT812593E (pt) 2002-01-30
JP4028593B2 (ja) 2007-12-26
HUT72916A (en) 1996-06-28
KR100310510B1 (ko) 2002-07-04
DK0689454T3 (da) 1997-12-08
CN1119829A (zh) 1996-04-03
DE69428136D1 (de) 2001-10-04
NZ263538A (en) 1996-10-28
AP515A (en) 1996-08-09
IL109056A (en) 1998-06-15
EP0812593B8 (en) 2010-11-10
EP0689454B2 (en) 2005-02-23
ATE204762T1 (de) 2001-09-15
DK0812593T4 (da) 2008-05-13
DE69405551D1 (de) 1997-10-16
NO20054701L (no) 1995-09-22
WO1994021292A1 (en) 1994-09-29
DE69428136T2 (de) 2002-05-02
PL310598A1 (en) 1995-12-27
CZ246795A3 (en) 1996-03-13
DZ1763A1 (fr) 2002-02-17
HK1045935A1 (zh) 2002-12-20
HK1011930A1 (en) 1999-07-23
NO322578B1 (no) 2006-10-30
EP0689454A1 (en) 1996-01-03
SA94140762B1 (ar) 2005-05-31
JP4837906B2 (ja) 2011-12-14
EP1175912A1 (en) 2002-01-30
EP0812593B1 (en) 2001-08-29
AU685443B2 (en) 1998-01-22
PL178578B1 (pl) 2000-05-31
HU219056B (hu) 2001-02-28
DK0689454T4 (da) 2005-05-30
US5776468A (en) 1998-07-07
JPH08508722A (ja) 1996-09-17
AP9400629A0 (en) 1994-04-30
NO20054701D0 (no) 2005-10-12
SK117395A3 (en) 1996-11-06
ES2109685T3 (es) 1998-01-16
ES2162139T3 (es) 2001-12-16
DE69405551T3 (de) 2005-10-20
ATE157882T1 (de) 1997-09-15
IL109056A0 (en) 1994-06-24
JP2005015487A (ja) 2005-01-20
FI110844B (fi) 2003-04-15
NO953759D0 (no) 1995-09-22
EP0812593A1 (en) 1997-12-17
ES2109685T5 (es) 2005-09-01
ES2162139T5 (es) 2008-05-16
EP0812593B2 (en) 2008-01-02
DE69428136T3 (de) 2008-07-10
DK0812593T3 (da) 2001-11-12
HU9501979D0 (en) 1995-08-28
MA23143A1 (fr) 1994-10-01
GR3025483T3 (en) 1998-02-27
NO953759L (no) 1995-09-22
SG48309A1 (en) 1998-04-17
FI954514A0 (fi) 1995-09-22
BR9405957A (pt) 1995-12-12
AU6426494A (en) 1994-10-11
EP0689454B1 (en) 1997-09-10
CN1087176C (zh) 2002-07-10
DE69405551T2 (de) 1998-03-26
FI954514A (fi) 1995-09-22

Similar Documents

Publication Publication Date Title
HK1023499A1 (en) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
SG48375A1 (en) Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
EP0349692A3 (en) Stereoscopic display
SG44558A1 (en) Stereoscopic display unit
EP0475502A3 (en) Head-up display
GB2272041B (en) Propeller shafts
EP0456411A3 (en) Graphics display system
EP0477889A3 (en) Full color three-dimensional display system
PL313979A1 (en) Vaccine composition
GB9326425D0 (en) Vaccine compositions
GB2251115B (en) Head-up display
AU4981493A (en) Three-dimensional image display
GB9008426D0 (en) Graphics display system
GB9306029D0 (en) Vaccine compositions
GB9320454D0 (en) Vaccine compositions
AU7541696A (en) A method of preparing vaccine compositions containing 3-0-deacylated monophosphoryl lipid A
AU122142S (en) Modular display
AU4762293A (en) Three-dimensional image display
GB9223483D0 (en) Display carton

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20140313